A retrospective follow-up in women who had received grafts of cryopreserved ovarian tissue discovered a 30% success rate in bearing a child.
Loss of fertility is a major quality of life concern for cancer patients treated with toxic chemotherapy. A study conducted in Denmark now offers hope to survivors to start a family after having recovered from their disease and its associated treatment.
Published in the journal Human Reproduction, the study retrospectively followed 41 Danish women who had a total of 53 transplantations of thawed ovarian tissue over a 10-year period. The authors of the study monitored these women for ovarian function, fertility outcome, and relapse in cancer survivors. Of the 32 women who wished to conceive, 24 clinical pregnancies were established, and 10 (about 31%) had a child/children (14 children born). Additionally, 2 legal abortions and 1 miscarriage in the second trimester occurred. In some of the women who had undergone the transplantation procedure, the ovarian tissue was functional for nearly a decade. While 3 women had disease relapse, the authors did not attribute it to the transplanted ovarian tissue.
The authors conclude that their study provides evidence for integrating cryopreservation of ovarian tissue into clinical practice for young women being treated for cancer if they are at risk of losing their fertility following treatment.
“As far as we know this is the largest series of ovarian tissue transplantation performed worldwide,” according to Annette Jensen, MD, the lead author on the study. “The fact that cancer survivors are now able to have a child of their own is an immense, quality-of-life boost for them,” she said. She added that while fertility preservation is increasingly being introduced in the mainstream, safety and efficacy studies are warranted.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More